Literature DB >> 10762021

COX-2 and colon cancer: potential targets for chemoprevention.

D B Fournier1, G B Gordon.   

Abstract

Evidence derived from several lines of investigation suggest that prostaglandins, metabolites of arachidonic acid, play an important role in colon cancer development. Elevated prostaglandin levels are found in colon cancers and their precursor lesions, adenomatous polyps. Agents such as aspirin and NSAIDs, which inhibit the generation of these arachidonic acid metabolites, are associated with a decreased risk of developing or dying from colon cancer. Both the amount of the agent used and the duration of exposure seem to be important variables. In animals, NSAIDs are among the most potent agents discovered for the reduction of tumors in both genetic and carcinogen-induced models. Data from human trials also suggests that NSAIDs such as sulindac can reduce the size and number of polyps in individuals with familial adenomatous polyposis (FAP). In parallel with the above findings, it is now understood that at least two forms of the enzyme responsible for the metabolism of arachidonic acid exist. One of these forms, COX-1, is generally considered a constitutive form that is responsible for maintaining normal physiologic function. Inhibition of COX-1 leads to many of the clinically undesirable side effects associated with NSAID use. The other known form of the enzyme, COX-2, is an inducible form that is found in increased levels in inflammatory states and in many cancers and their associated pre-malignant lesions. Levels of COX-2 are increased by exposure to mitogens and growth factors. Agents that specifically inhibit COX-2 are now in clinical development and appear to be well-tolerated and effective for the treatment of osteoarthritis and rheumatoid arthritis. The potential for use of COX-2 specific NSAIDs in the prevention of colon cancer is suggested from the distribution of COX-2 in adenomatous polyps and colon cancer and the effectiveness of these agents in genetic and carcinogen-induced animal models of colon cancer. The development of these agents for the prevention of colon cancer will be discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762021     DOI: 10.1002/(sici)1097-4644(2000)77:34+<97::aid-jcb16>3.0.co;2-z

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN: 0733-1959


  19 in total

1.  Perils of immunohistochemistry: variability in staining specificity of commercially available COX-2 antibodies on human colon tissue.

Authors:  Harinder Garewal; Lois Ramsey; Ronnie Fass; Nancy K Hart; Claire M Payne; Harris Bernstein; Carol Bernstein
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

2.  Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.

Authors:  C C Wong; Ka-Wing Cheng; Basil Rigas
Journal:  J Pharmacol Exp Ther       Date:  2012-03-23       Impact factor: 4.030

3.  Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation.

Authors:  Guofeng Xie; Zhongsheng Peng; Jean-Pierre Raufman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-23       Impact factor: 4.052

Review 4.  Phospholipid remodeling and eicosanoid signaling in colon cancer cells.

Authors:  Siddhartha Das; Leobarda Robles Martinez; Suparna Ray
Journal:  Indian J Biochem Biophys       Date:  2014-12       Impact factor: 1.918

5.  Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2.

Authors:  Yi Xu; Xiaoyu Yang; Pinjing Zhao; Zhongyu Yang; Changhui Yan; Bin Guo; Steven Y Qian
Journal:  Free Radic Biol Med       Date:  2016-04-19       Impact factor: 7.376

6.  Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.

Authors:  Dong-Sheng Huang; Ke-Zhen Shen; Jian-Feng Wei; Ting-Bo Liang; Shu-Sen Zheng; Hai-Yang Xie
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

7.  Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line.

Authors:  Jian-Ying Li; Xiao-Zhong Wang; Feng-Lin Chen; Jie-Ping Yu; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

8.  The PGF(2alpha) receptor FP is lost in nevi and melanoma.

Authors:  Alex Fricke; Lindy McClelland; Glynis Scott
Journal:  Pigment Cell Melanoma Res       Date:  2009-12-11       Impact factor: 4.693

9.  Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma.

Authors:  Xiao-Li Chen; Bao-Shan Su; Run-Qin Sun; Jun Zhang; Yi-Li Wang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

Review 10.  Arachidonic acid and colorectal carcinogenesis.

Authors:  Raymond Jones; Luis-Alfonso Adel-Alvarez; Osvaldo Rascon Alvarez; Russell Broaddus; Siddhartha Das
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.